Economic aspects of COVID-19 treatment in a hospital setting

Abstract

In April 2020 in order to prevent the spread of the new coronavirus infection COVID-19 on the territory of the Russian Federation, strict quarantine measures were introduced. In the shortest possible time, a large number of general hospitals were repurposed into COVID hospitals, recommendations were issued on the management of patients with a new coronavirus infection based on the existing global experience. The limited resources of the healthcare system in a pandemic require research into the pharmacoeconomic aspects of COVID-19. In the course of the study, a continuous retrospective analysis of the case histories of 6255 patients admitted to the Central Clinical Hospital RZD-Medicine was carried out. During the study period, 22% of patients received biological therapy. The average mortality rate of patients on biological therapy is 11.6%. An individual selection of the therapeutic dose of low molecular weight heparins was carried out, which showed high clinical efficacy. The developed methods were assessed from the perspective of pharmacoeconomics. The increase in the degree of damage to the lung tissue in patients with COVID-19, as well as the presence of concomitant diseases, entails an increase in the cost of treatment. Biotherapy can reduce the cost of treating patients with CT-4 by 16% by reducing the length of stay in the intensive care unit, the need for mechanical ventilation and reducing mortality.

Keywords:pharmacoeconomics, COVID-19, biological therapy, low molecular weight heparins, pandemic

Funding. The study was not sponsored.

Conflict of interest. The authors declare that there is no conflict of interest.

Contribution. Study design – Zhidkova E.A.; collection of clinical material – Shaburov R.I., Cheremushkin S.V., Gubkin A.V.; pharmacoeconomic modeling – Rogova I.V., Popova I.A.; writing an article – Gurevich K.G.

For citation: Zhidkova E.A., Shaburov R.I., Cheremushkin S.V., Gubkin A.V., Rogova I.V., Popova I.A., Gurevich K.G. Economic aspects of COVID-19 treatment in a hospital setting. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2021; 10 (3): 41–8. DOI: https://doi.org/10.33029/2305-3496-2021-10-3-41-48 (in Russian)

1. Khatana S.A.M., Groeneveld P.W. Health disparities and the coronavirus disease 2019 (COVID-19) pandemic in the USA. J Gen Intern Med. 2020; 35 (8): 2431–2. DOI: https://doi.org/10.1007/s11606-020-05916-w

2. Bragina A.V., Pilipenko D.V., Akhmadeev D.R. Impact of COVID-19 and the crisis caused by it on the Russian economy. E-Scio. 2020; (8): 9–15. (in Russian)

3. Borisevich S.V., Sizikova T.E., Lebedev V.N. COVID-19 Pandemic: analysis of possible scenarios for the development of the epidemic in Russia. Vestnik voysk RKhB zashchity [Bulletin of the RKhB Protection Troops]. 2020; 4 (2): 116–30. DOI: https://doi.org/10.35825/2587-5728-2020-4-2-116-130 (in Russian)

4. Budarin S.S. Sustainability of global health systems during the COVID-19 pandemic. Ekonomika i upravlenie: problemy, resheniya [Economics and Management: Problems, Solutions]. 2020; 3 [8 (104)]: 105–14. DOI: https://doi.org/10.34684/ek.up.p.r.2020.08.03.013 (in Russian)

5. Nikitin I.G., Melekhov A.V., Sayfullin M.A., Agafonov S.S., Bedritsky S.A., Vishninsky A.A., et al. Organizing the medical care for the COVID-19 patients in non-infectious Moscow hospital: reassignment experience. Terapevticheskiy arkhiv [Therapeutic Archive]. 2020; 92 (11): 31–7. DOI: https://doi.org/10.26442/00403660.2020.11.000838 (in Russian)

6. Li G., Ruan S., Zhao X., Liu Q., Dou Y., Mao F. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. Comput Struct Biotechnol J. 2021; 19: 1–15. DOI: https://doi.org/10.1016/j.csbj.2020.11.056

7. Tripathi N., Tripathi N., Goshisht M.K. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. Mol Divers. 2021; Jan 5: 1–17. DOI: https://doi.org/10.1007/s11030-020-10176-1

8. Kotenko O.N., Vinogradov V.E., Dorofeeva E.G., Vasina N.V., Ivanova E.S., Berdinsky V.A., et al. Organization of outpatient care after organ transplantation during the pandemic of the new coronavirus infection COVID-19 in Moscow. Vestnik transplantologii i iskusstvennykh organov [Bulletin of Transplantology and Artificial Organs]. 2020; 22 (S): 174–5. (in Russian)

9. Golukhova E.Z., Slivneva I.V., Rybka M.M., Mamalyga M.L., Alekhin M.N., Klyuchnikov I.V., et al. Pulmonary hypertension as a risk assessment factor for unfavorable outcome in patients with COVID-19. Rossiiskii kardiologicheskii zhurnal. 2020; 25 (12): 121–33. DOI: https:// doi.org/10.15829/1560-4071-2020-4136 (in Russian)

10. Alcocer-Díaz-Barreiro L., Cossio-Aranda J., Verdejo-Paris J., Odinde-Los-Ríos M., Galván-Oseguera H., Álvarez-López H., et al. COVID-19 and the renin, angiotensin, aldosterone system. A complex relationship. Arch Cardiol Mex. 2020; 90 (suppl): 19–25. DOI: https://doi.org/10.24875/ ACM.M20000063

11. Samsonova M.V., Mikhaleva L.M., Zairat’yants O.V., Varyasin V.V., Bykanova A.V., Mishnev O.D., et al. Lung Pathology of COVID-19 in Moscow. Arkhiv patologii [Archive of Pathology]. 2020; 82 (4): 32–40. DOI: https:// doi.org/10.17116/patol20208204132 (in Russian)

12. Svistunov A.A., Khorobrykh T.V., Makhnach G.K., Krylov A.Yu., Bunina D.V., Volgin M.V., et al. Experience of immunomodulators use for prevention of COVID-19 infection among health care personnel and avoidance of COVID-induced pneumonia complications in patients with СОVID-19. Terapiya [Therapy]. 2020; 6 [7 (41)]: 156–64. DOI: https://doi. org/10.18565/therapy.2020.7.156-164 (in Russian)

13. Kolbin A.S. An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Infektsiya i immunitet [Infection and Immunity]. 2020; 10 (2): 277–86. DOI: https://doi.org/10.15789/2220-7619-AEA-1458 (in Russian).

14. Vechorko V.I., Silaev B.V., Tan’shina O.V., Zhenina E.A. Preparation and results of work in a multi -specialty hospital in the context of the COVID-19 pandemic. Byulleten’ natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya imeni N.A. Semashko [Bulletin of the National Research Institute of Public Health named after N.A. Semashko]. 2020; (4): 46–51. DOI: https://doi.org/10.25742/NRIPH.2020.04.006 (in Russian)

15. Zakharova E.G., Vechorko V.I., Zhenina E.A., Gumenyuk S.A. Experience of reprofiling the reception department of a multi-disciplinary hospital under the conditions of the COVID-19 epidemic. Profilakticheskaya meditsina [Preventive Medicine]. 2020; 23 (8): 14–8. DOI: https://doi. org/10.17116/profmed20202308114 (in Russian)

16. Dondorp A.M., Hayat M., Aryal D., Beane A., Schultz M.J. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020; 102 (6): 1191–7. DOI: https://doi.org/10.4269/ ajtmh.20-0283

17. Gubkin A.V., Shaburov R.I., Cheremushkin S.V., Latypov R.S., Rybina O.V., Ataulakhanov F.I. Features of diagnostics and treatment of dic syndrome in patients with COVID-19. Gematologiya. Transfuziologiya. Vostochnaya Evropa [Hematology. Transfusiology. Eastern Europe]. 2021; 7 (1): 90–7. DOI: https://doi.org/10.34883/PI.2021.7.1.008 (in Russian)

18. Zhukova O.V., Khokhlov A.L. Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya [Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology]. 2021; 14 (1): 16–27. DOI: https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.060 (in Russian)

19. Potere N., Batticciotto A., Vecchié A., et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021. May 27. P. 1–17. DOI: https://doi.org/10.1080/1744666X.2021.1919086

20. Chen L.Y.C., Biggs C.M., Jamal S., et al. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome. Cell Rep Med. 2021; Apr 19: 100269. DOI: https://doi.org/10.1016/j.xcrm.2021.100269

21. McElvaney O.J., Curley G.F., Rose-John S., et al. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021; Apr 16: S2213-2600(21)00103-X. DOI: https://doi. org/10.1016/S2213-2600(21)00103-X

22. Angriman F., Ferreyro B.L., Burry L., et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021; Apr 27: S2213-2600(21)00139-9. DOI: https:// doi.org/10.1016/S2213-2600(21)00139-9

23. Flisiak R., Jaroszewicz J., Rogalska M., et al. Tocilizumab improves the prognosis of COVID-19 in patients with high IL-6. J Clin Med. 2021; 10 (8): 1583. DOI: https://doi.org/10.3390/jcm10081583

24. Meanwatthana J., Majam T. Interleukin-6 antagonists: lessons from cytokine release syndrome to the therapeutic application in severe COVID-19 infection. J Pharm Pract. 2021; Mar 24: 8971900211000691. DOI: https://doi.org/10.1177/08971900211000691

25. Tleyjeh I.M., Kashour Z., Riaz M. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis: first update. Clin Microbiol Infect. 2021; Apr 26: S1198-743X(21)00204-4. DOI: https://doi.org/10.1016/j.cmi.2021.04.019

26. Klopfenstein T., Gendrin V., Kadiane-Oussou J. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2021; Apr 21: e2239. DOI: https://doi. org/10.1002/rmv.2239

27. Mehta M., Purpura L.J., McConville T.H., et al. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. PLoS One. 2021; 16 (4): e0249349. DOI: https://doi. org/10.1371/journal.pone.0249349

28. Ascierto P.A., Fu B., Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021; 9 (4): e002285. DOI: https://doi.org/10.1136/jitc-2020-002285

29. Keragala C.B., Medcalf R.L., Myles P.S., et al. Fibrinolysis and COVID-19: a tale of two sites? J Thromb Haemost. 2020; 18 (9): 2430–2. DOI: https://doi.org/10.1111/jth.15017

30. Medcalf R.L., Keragala C.B., Myles P.S. Fibrinolysisand COVID-19: a plasminparadox. J Thromb Haemost. 2020; 18: 2118–22. DOI: https:// doi.org/10.1111/jth.14960

31. Tang N., Bai H., Xiong D., Sun Z. Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. J Thromb Haemost. 2020; 18 (9): 2428–30. DOI: https://doi.org/10.1111/jth.14988

32. Bachler M., Bösch J., Stürzel D.P., et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth. 2021; 126 (3): 590–8. DOI: https://doi.org/10.1016/j.bja.2020.12.010

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»